Skip to main content
. 2024 Aug 28;598:217106. doi: 10.1016/j.canlet.2024.217106

Fig. 3.

Fig. 3

Drug-induced cellular senescence in DPDOs with up-regulation of MCP-1/CCL2. (a) The positive rate of SA-β-GAL staining is increased in both DPDO1 and DPDO2 after Danusertib or Barasertib-HQPA treatment (1 μM，96 h). n = 10，scale bar = 30 μm. (b) Compared to NC group, enlarged cancer cells with multinucleated giant cell changes are observed in Danusertib or Barasertib-HQPA treated group by Giemsa staining. scale bar = 20 μm (c) The bar chart shows increased positive rate of SA-β-GAL in six aging PDOs relative to eight early passage PDOs. (d) The heatmap shows inflammatory factors concentration of culture supernatants from active PDOs and aging PDOs. The red box marks the up-regulation of MCP-1/CCL2. (e) The bar chart presents the concentration difference of MCP-1/CCL2 between aging PDOs and active PDOs. (f) The bar chart shows concentration difference of MCP-1/CCL2 in the culture supernatants of NC group and Danusertib or Barasertib-HQPA-treated groups (1 μM, 96 h) in DPDO1 and DPDO2 cases. n = 3; nsP> 0.05; **P < 0.01; ***P < 0.001.